LOGIN  |  REGISTER
Assertio
Recursion

Syra Health To Discuss First Quarter 2024 Financial Results

May 01, 2024 | Last Trade: US$0.40 0.02 5.99
  • Conference call will be held on Thursday, May 9 at 9:00 AM ET

CARMEL, Ind., May 1, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it will report financial results for its first quarter 2024 ended March 31, 2024, on Thursday, May 9, 2024, before the market opens. The Company has scheduled a conference call that same day, May 9, 2024, at 9:00 a.m. ET, to review the results.

Interested parties can access the conference call via Internet webcast, which is available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q1-2024-earnings-call.

Investors who would like to submit a question to be addressed on the call should email the question to This email address is being protected from spambots. You need JavaScript enabled to view it..

A webcast replay will be available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q1-2024-earnings-call.

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental healthdigital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.

For more information, please contact:

For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB